ClinicalTrials.Veeva

Menu

Reducing Hazardous Alcohol Use and Optimizing Treatment as Prevention Among Men Living With HIV in Risk Environments (Kisoboka)

San Diego State University logo

San Diego State University

Status

Enrolling

Conditions

HIV Antiretroviral Therapy (ART) Adherence
HIV Infection
Alcohol Abuse
HIV Infections
Alcohol Use Disorder

Treatments

Behavioral: Screening and Referral
Behavioral: Behavioral Economics
Behavioral: Kisoboka
Behavioral: Motivational Interviewing

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT06771843
R01AA031650 (U.S. NIH Grant/Contract)
HS-2024-0086

Details and patient eligibility

About

The investigators developed the Kisoboka ("It is possible") Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in "risk environments" such as fishing communities through reductions in hazardous alcohol use, improved adherence to HIV medications and achieving undetectable HIV viral loads.

Social and structural determinants unique to fishing communities interact to create a risk environment where hazardous drinking impedes adherence to HIV medications among men living with HIV, including prevalent social norms of drinking, drinking as a way of experiencing "reward" and connecting with others (e.g. in the context of transactional sex), stressful work conditions, a "live for today" outlook, and a cash-based economy with no traditional savings infrastructure leading to ease of daily expenditure on drinking and sex work. These social and environmental conditions result in high levels of alcohol misuse and HIV risk, poor HIV outcomes, and exacerbation of HIV-associated wellness comorbidities such as poor mental and subjective physical health and food insecurity.

The goal of this study is to learn if the intervention called Kisoboka works to help men in fishing communities reduce hazardous alcohol use, be better able to take the participants HIV medication as prescribed, and have undetectable HIV viral loads. The investigators will compare the Kisoboka intervention to a brief alcohol screening, adherence counseling, and referrals, and to components of the Kisoboka intervention.

Participants will attend intervention counseling sessions according to the study arm to which the participants are randomly assigned. The number of sessions ranges from 1 to 6 over 1 to 16 weeks and are individual only or both individual and group sessions.

Enrollment

716 estimated patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. living with HIV;
  2. residing in a fishing community (on most days/nights);
  3. AUDIT-C positive (≥4) indicating potential hazardous drinking;
  4. >6 months since initial antiretroviral treatment (ART) initiation;
  5. not planning to move from the area within the next 6 months;
  6. have their own mobile phone and can be reached via phone.
  7. an indicator of potential suboptimal treatment as prevention (TasP) either:

(i) last HIV viral load test (within 6 months) was detectable (>20) or (ii) last viral load test between 6 and 13 months ago was detectable (>20) and reports missing ≥2 ART doses in the past 2 weeks or (iii) a lack of viral load test results for the prior 13 months in clinic records and reports missing ≥2 ART doses in the past 2 weeks;

Exclusion criteria

  1. visibly intoxicated at enrollment (eligible to enroll when not intoxicated);
  2. does not speak Luganda or English;
  3. currently receiving a majority of work payments via mobile money/digital payments;
  4. participated in the Kisoboka pilot RCT;
  5. unable to read basic Luganda or English

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Double Blind

716 participants in 4 patient groups

Kisoboka (BE + MI and synergy)
Experimental group
Treatment:
Behavioral: Kisoboka
Behavioral Economics (BE)
Experimental group
Treatment:
Behavioral: Behavioral Economics
Motivational Interviewing (MI)
Experimental group
Treatment:
Behavioral: Motivational Interviewing
Screening and Referral (S&R)
Active Comparator group
Treatment:
Behavioral: Screening and Referral

Trial contacts and locations

1

Loading...

Central trial contact

Joseph Matovu, PhD, MHS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems